Arrowhead Promotes David Lewis to Chief Scientific Officer
Steven Kanner Joins the Company as Vice President of Biology
PASADENA, Calif. -- September 19, 2013
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced the promotion of David
Lewis, Ph.D., to Chief Scientific Officer. In this position, Dr. Lewis will
have overall scientific leadership responsibilities for RNA delivery,
discovery, and pre-clinical development of new drug candidates.
Dr. Lewis is a leading expert in nucleic acid delivery and RNAi therapeutics
with over ten years of experience in the field. He is a co-inventor of the
Dynamic Polyconjugate^® (DPC) technology for targeted delivery of siRNA and
led the discovery and pre-clinical development program for ARC-520,
Arrowhead’s clinical candidate against chronic hepatitis B virus infection.
“Dave has served as the site head of the R&D facility in Madison for the last
3 years and has done a superb job of leading ARC-520 into clinical development
and, in the process, expanding the site’s development capabilities rapidly,”
said Bruce D. Given, MD, COO and Head of R&D for Arrowhead. “This recognition
of his performance is richly deserved.”
Arrowhead is also pleased to announce that Steven Kanner, Ph.D., has joined
the company as Vice President of Biology to assume Dr. Lewis’ prior
responsibilities in this role. Dr. Kanner was previously Vice President,
Discovery Biology at Astex Pharmaceuticals and held leadership and research
roles at Agensys, Astellas, and Bristol-Myers Squibb. He received his B.A.
degree in Genetics from the University of California-Berkeley, and his Ph.D.
degree in Immunology and Microbiology from the University of Miami School of
Approximately 350 million people worldwide are chronically infected with the
hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver
and is responsible for 80% of primary liver cancers globally. Arrowhead’s
RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by
reducing the expression and release of new viral particles and key viral
proteins. The goal is to achieve a functional cure, which is an immune
clearant state characterized by hepatitis B s-antigen negative serum with or
without sero-conversion. The siRNAs in ARC-520 intervene at the point of DNA
transcription, upstream of where nucleotide and nucleoside analogues act. In
transient and transgenic mouse models of HBV infection, a single co-injection
of Arrowhead’s DPC delivery vehicle with cholesterol-conjugated siRNA
targeting HBV sequences resulted in multi-log knockdown of HBV RNA, proteins
and viral DNA with long duration of effect. In a chimpanzee chronically
infected with HBV and high viremia and antigenemia, ARC-520 induced rapid
reductions of 90-95% in HBV DNA, e-antigen, and s-antigen. Arrowhead is
conducting a phase 1 single ascending dose study in normal volunteers, which
the company expects to follow with a phase 2a study in chronic HBV patients.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to email@example.com
As an inducement to his entering into employment with the Company on September
16, 2013, Dr. Kanner was awarded an "inducement" option under Rule 5635(c)(4)
of the NASDAQ Marketplace Rules. The option entitles Dr. Kanner to purchase,
outside of the Company's stockholder approved equity incentive plans, an
aggregate of up to 50,000 shares of the Company's common stock at an exercise
price per share of $4.65, the last reported closing price of the Company's
common stock on the date of grant. The option vests and becomes exercisable
over a period of four years from the date of grant.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Lauren Glaser, 646-378-2972
Press spacebar to pause and continue. Press esc to stop.